Brief: Sangamo Therapeutics Announces U.S. FDA Alignment On Abbreviated Pathway To Potential Approval For St-920 In Fabry Disease

Sangamo Therapeutics

12/02/2024 13:08

Feb 12 (Reuters) - Sangamo Therapeutics Inc  SGMO.O :
    * SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA ALIGNMENT ON
ABBREVIATED
PATHWAY TO POTENTIAL APPROVAL AND EMA PRIME ELIGIBILITY FOR
ST-920 IN FABRY DISEASE
    * ACTIVELY SEEKING A COLLABORATION PARTNER TO ADVANCE
ISARALGAGENE
CIVAPARVOVEC THROUGH POTENTIAL REGISTRATION AND
COMMERCIALIZATION.
    * ACTIVELY SEEKING A COLLABORATION PARTNER TO ADVANCE
ISARALGAGENE
CIVAPARVOVEC THROUGH POTENTIAL REGISTRATION AND
COMMERCIALIZATION
    * SANGAMO IS ACTIVELY SEEKING A COLLABORATION PARTNER TO
ADVANCE
ISARALGAGENE CIVAPARVOVEC THROUGH POTENTIAL REGISTRATION AND
COMMERCIALIZATION.
    * EMA HAS GRANTED PRIME ELIGIBILITY TO ISARALGAGENE
CIVAPARVOVEC
    * IS DEFERRING ADDITIONAL INVESTMENTS IN PLANNING FOR A
REGISTRATIONAL TRIAL UNTIL A COLLABORATION PARTNERSHIP IS
SECURED
    * DEFERRING ADDITIONAL INVESTMENTS IN PLANNING FOR A
REGISTRATIONAL TRIAL UNTIL A COLLABORATION PARTNERSHIP IS
SECURED

Source text for Eikon:  ID:nBwbM4ZXHa 
Further company coverage:  SGMO.O 

 ((Reuters.Briefs@thomsonreuters.com;))